本文選題：收購方式 + 企業(yè)價(jià)值�。� 參考：《哈爾濱工業(yè)大學(xué)》2014年碩士論文

【摘要】：醫(yī)藥產(chǎn)業(yè)是與人民群眾生命健康和生活質(zhì)量等切身利益息息相關(guān)的全社會(huì)關(guān)注的熱點(diǎn)問題，是市場經(jīng)濟(jì)的重要組成部分，隨著國家政策的變化和醫(yī)療改革的推行，我國醫(yī)藥行業(yè)在進(jìn)行著行業(yè)變革，迅猛發(fā)展背后的問題逐漸凸顯：資產(chǎn)結(jié)構(gòu)不合理、環(huán)保治理能力較弱、資源嚴(yán)重浪費(fèi)、創(chuàng)新能力較差等等。因此，企業(yè)的兼并和重組可以說是市場經(jīng)濟(jì)發(fā)展的必然趨勢，也是實(shí)現(xiàn)醫(yī)藥工業(yè)繁榮的必經(jīng)之路。 本文側(cè)重于我國企業(yè)收購具體案例的價(jià)值研究，即對(duì)擬收購公司的價(jià)值進(jìn)行預(yù)估。企業(yè)收購是一項(xiàng)涉及關(guān)系和問題眾多的復(fù)雜的系統(tǒng)工程，首先需要對(duì)這些問題進(jìn)行認(rèn)真細(xì)致的背景分析，為企業(yè)日后的收購行為提供科學(xué)根據(jù)。本文從介紹收購企業(yè)和被收購企業(yè)開始入手，結(jié)合市場情況和政策導(dǎo)向，以及收購方所處的企業(yè)瓶頸，具體分析了收購方企業(yè)所存在的問題，然后根據(jù)企業(yè)的具體情況和行業(yè)市場政策導(dǎo)向等，確定了目標(biāo)企業(yè)，并對(duì)目標(biāo)企業(yè)進(jìn)行了市場分析以及優(yōu)勢和問題分析，在以上分析的基礎(chǔ)上，分析了收購項(xiàng)目可行性以及必要性。然后設(shè)計(jì)了收購方案的主要控制點(diǎn)，首先根據(jù)目標(biāo)企業(yè)的實(shí)際財(cái)務(wù)數(shù)據(jù)，對(duì)整個(gè)收購方案的經(jīng)濟(jì)價(jià)值進(jìn)行了預(yù)測，提出收購項(xiàng)目的投資計(jì)劃以及資金需求和具體的融資方案，并對(duì)項(xiàng)目進(jìn)行了效益評(píng)價(jià)，即財(cái)務(wù)預(yù)測。并提出了收購項(xiàng)目的業(yè)績保障方案，以降低收購項(xiàng)目的風(fēng)險(xiǎn)性。最后進(jìn)行了收購項(xiàng)目的價(jià)值分析，這里采取了自由現(xiàn)金流量方法評(píng)估目標(biāo)企業(yè)的價(jià)值，并對(duì)企業(yè)價(jià)值進(jìn)行了敏感性分析，確立了企業(yè)收購價(jià)值的適合區(qū)間，，得出收購的最高限價(jià)，并結(jié)合收購企業(yè)雙方的財(cái)務(wù)情況，提出具體的支付方式。希望通過本文的撰寫，對(duì)企業(yè)收購活動(dòng)提供一定的指導(dǎo)，尤其是醫(yī)藥行業(yè)的收購，對(duì)其收購過程中計(jì)算確定企業(yè)價(jià)值、支付方式的確定和收購價(jià)值測算提供一些思路和設(shè)想。同時(shí)，哈藥股份收購案例具有醫(yī)藥公司收購的典型性，通過研究這一收購案例，可以為其他上市公司，尤其是醫(yī)藥公司的收購方案設(shè)計(jì)提供借鑒意義。
[Abstract]:The pharmaceutical industry is a hot issue closely related to the vital interests of the people, such as life, health and quality of life. It is an important part of the market economy. With the change of national policy and the implementation of medical reform, The problems behind the rapid development of the pharmaceutical industry in China are becoming increasingly prominent: irrational asset structure, weak ability of environmental protection, serious waste of resources, poor ability of innovation and so on. Therefore, the merger and reorganization of enterprises can be said to be the inevitable trend of the development of market economy and the only way to realize the prosperity of pharmaceutical industry. This paper focuses on the value study of the specific case of enterprise acquisition in China, that is, to estimate the value of the company to be acquired. Enterprise acquisition is a complex system engineering involving many relations and problems. First of all, it is necessary to make a careful background analysis of these problems to provide scientific basis for the acquisition behavior of enterprises in the future. This paper begins with the introduction of the acquired enterprise and the acquired enterprise, combining with the market situation and the policy orientation, and the bottleneck of the enterprise in which the acquirer is located, and analyzes the existing problems of the acquirer's enterprise in detail. Then according to the specific situation of the enterprise and the market policy orientation of the industry, the target enterprise is determined, and the market analysis, advantage and problem analysis of the target enterprise are carried out, on the basis of the above analysis, The feasibility and necessity of acquisition project are analyzed. Then the main control points of the acquisition project are designed. Firstly, according to the actual financial data of the target enterprise, the economic value of the whole acquisition project is forecasted, and the investment plan, the capital demand and the specific financing plan of the acquisition project are put forward. And carried on the benefit appraisal to the project, namely the financial forecast. In order to reduce the risk of the acquisition project, the performance guarantee scheme of the acquisition project is put forward. Finally, the value analysis of the acquisition project is carried out. Here the free cash flow method is adopted to evaluate the value of the target enterprise, and the sensitivity analysis of the enterprise value is carried out, and the suitable interval of the enterprise acquisition value is established. The maximum price of the acquisition is obtained, and combined with the financial situation of both parties, the specific payment method is put forward. It is hoped that through the writing of this paper, it will provide some guidance for the enterprise acquisition, especially the acquisition in the pharmaceutical industry, and provide some ideas and assumptions for the calculation and determination of the enterprise value, the determination of the payment method and the measurement of the acquisition value in the course of its acquisition. At the same time, the purchase case of Harbin Pharmaceutical shares has the typical nature of the acquisition of pharmaceutical companies, through the study of this acquisition case, can provide reference for other listed companies, especially pharmaceutical companies.
【學(xué)位授予單位】：哈爾濱工業(yè)大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2014
【分類號(hào)】：F426.72;F406.7

【參考文獻(xiàn)】

相關(guān)期刊論文 前7條

1 余光,楊榮;企業(yè)購并股價(jià)效應(yīng)的理論分析和實(shí)證分析[J];當(dāng)代財(cái)經(jīng);2000年07期

2 李善民;周小春;;公司特征、行業(yè)特征和并購戰(zhàn)略類型的實(shí)證研究[J];管理世界;2007年03期

3 張毅;;我國醫(yī)藥行業(yè)并購重組現(xiàn)狀研究[J];科技情報(bào)開發(fā)與經(jīng)濟(jì);2006年07期

4 丁輝;;對(duì)我國醫(yī)藥行業(yè)并購重組發(fā)展趨勢的探討[J];江蘇科技信息;2011年03期

5 吳夕暉;;論中國企業(yè)兼并過程中存在的問題[J];商場現(xiàn)代化;2007年03期

6 陳玲;鄒栩;;全球制藥企業(yè)兼并與重組策略[J];中國醫(yī)藥導(dǎo)報(bào);2008年07期

7 楊舒杰;陳晶;王淑玲;;我國醫(yī)藥企業(yè)并購行為研究[J];中國藥業(yè);2011年06期

本文編號(hào)：1858106